Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lukai Zheng, Chunsong Yang, Lingbao Xiang & Zilong Hao. (2019) Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers 24:6, pages 517-523.
Read now
Read now
Articles from other publishers (19)
Sasidharan Pillai V Aswathy, Kotha Rohith Chandra, Pakkath Jyothikrishna & Kanniappan Parthasarathy Arun. (2022) Dosage optimization of clopidogrel via a precision medicine approach: the way forward. Pharmacogenomics 23:3, pages 195-206.
Crossref
Crossref
Alireza Tafazoli, Henk-Jan Guchelaar, Wojciech Miltyk, Adam J. Kretowski & Jesse J. Swen. (2021) Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology 12.
Crossref
Crossref
Anna Lichota, Eligia M. Szewczyk & Krzysztof Gwozdzinski. (2020) Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds. International Journal of Molecular Sciences 21:21, pages 7975.
Crossref
Crossref
Sawsan AlMukdad, Hazem Elewa & Daoud Al-Badriyeh. (2020) Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 25:3, pages 201-211.
Crossref
Crossref
Olivia M. Dong, Stephanie B. Wheeler, Gracelyn Cruden, Craig R. Lee, Deepak Voora, Stacie B. Dusetzina & Tim Wiltshire. (2020) Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health 23:1, pages 61-73.
Crossref
Crossref
Yota Koyabu, Shichiro Abe, Masashi Sakuma, Tomoaki Kanaya, Syotaro Obi, Shuichi Yoneda, Shigeru Toyoda, Toshiaki Nakajima & Teruo Inoue. (2019) Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Internal Medicine 58:16, pages 2315-2322.
Crossref
Crossref
Xiaoye Li, Zi Wang, Qibing Wang, Qing Xu & Qianzhou Lv. (2019) Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. Basic & Clinical Pharmacology & Toxicology 124:1, pages 84-93.
Crossref
Crossref
Craig R. LeeVindhya B. SriramojuAlexandra CervantesLucius A. HowellNicholas VarunokShivanshu MadanKasey HamrickMelissa J. PolasekJohn Andrew LeeMegan ClarkeJonathan D. CicciKaren E. WeckGeorge A. Stouffer. (2018)
Clinical Outcomes and Sustainability of Using
CYP2C19
Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
. Circulation: Genomic and Precision Medicine 11:4.
Crossref
Crossref
Y Wang, B P Yan, D Liew & V W Y Lee. (2017) Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. The Pharmacogenomics Journal 18:1, pages 113-120.
Crossref
Crossref
Mrudula S Borse, Olivia M Dong, Melissa J Polasek, Joel F Farley, George A Stouffer & Craig R Lee. (2017)
CYP2C19
-guided antiplatelet therapy: a cost–effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention
. Pharmacogenomics 18:12, pages 1155-1166.
Crossref
Crossref
Adriana Isvoran, Maxime Louet, Diana Larisa Vladoiu, Dana Craciun, Marie-Anne Loriot, Bruno O. Villoutreix & Maria A. Miteva. (2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discovery Today 22:2, pages 366-376.
Crossref
Crossref
Minghuan Jiang & Joyce H. S. You. (2016) CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovascular Drugs and Therapy 31:1, pages 39-49.
Crossref
Crossref
Martin Petrek, Lenka Kocourkova, Veronika Zizkova, Zdenek Nosek, Milos Taborsky & Jana Petrkova. (2017) Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre. Archivum Immunologiae et Therapiae Experimentalis 64:S1, pages 99-107.
Crossref
Crossref
Minghuan Jiang & Joyce HS You. (2016) Cost–effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics 17:7, pages 701-713.
Crossref
Crossref
Francesca Wirth, Graziella Zahra, Robert G. Xuereb, Christopher Barbara, Albert Fenech & Lilian M. Azzopardi. (2016) Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. International Journal of Clinical Pharmacy 38:2, pages 414-420.
Crossref
Crossref
Kurt Christensen, Dmitry Dukhovny, Uwe Siebert & Robert Green. (2015) Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. Journal of Personalized Medicine 5:4, pages 470-486.
Crossref
Crossref
Minghuan Jiang & Joyce H.S. You. (2015) CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. Pharmacogenetics and Genomics 25:12, pages 609-617.
Crossref
Crossref
Joyce HS You. (2015) Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics 16:10, pages 1089-1100.
Crossref
Crossref
Javier Andreu-Perez, Carmen C. Y. Poon, Robert D. Merrifield, Stephen T. C. Wong & Guang-Zhong Yang. (2015) Big Data for Health. IEEE Journal of Biomedical and Health Informatics 19:4, pages 1193-1208.
Crossref
Crossref